Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Magnetic resonance imaging effects of interferon beta-1b in the BENEFIT study: integrated 2-year results.
In vivo time-lapse imaging shows dynamic oligodendrocyte progenitor behavior during zebrafish development.
Gray matter SWI-filtered phase and atrophy are linked to disability in MS .
Progressive Loss of Retinal Ganglion Cells and Axons in Nonoptic Neuritis Eyes in Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.
Extensive bilateral lower extremity deep venous thrombosis in a patient on dimethyl fumarate.
Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan.
Biologics-induced autoimmune diseases.
Autoimmune AQP4 channelopathies and neuromyelitis optica spectrum disorders.
Iran mass produces MS drug Ziferon
Modulation of immune function occurs within hours of therapy initiation for multiple sclerosis.
Clinical utility of testing AQP4-IgG in CSF: Guidance for physicians.
Retinyl Palmitate Supplementation Modulates T-bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients.
Comprehensive follow-up of the first genome-wide association study of multiple sclerosis identifies KIF21B and TMEM39A as susceptibility loci.
Clinical utility of the list sign as a predictor of non-demyelinating disorders in a multiple sclerosis (MS) practice.
Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results.
A Pilot Trial of Interferon beta-1a in Alzheimer's Disease
An update on the evidence for the efficacy and safety of rituximab in the management of neuromyelitis optica.
Estriol Treatment in Multiple Sclerosis: Effect on Cognition
Multiple sclerosis in pregnancy.
EMD Serono Takes on Exclusive Promotion of Rebif® (interferon beta-1a) in the US
Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels. Rapid communication.
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis.
Clinical efficacy assessment in photodamaged skin of 0.5% and 1.0% idebenone.
Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Biogen Idec reports death of patient on its MS pill

Pages